Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Rating of “Hold” by Analysts

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have been assigned a consensus recommendation of “Hold” from the ten brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company.

A number of equities research analysts recently weighed in on the stock. Wolfe Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Zacks Research cut shares of Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 13th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Finally, Jefferies Financial Group downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF opened at $47.64 on Monday. Zealand Pharma A/S has a 12-month low of $35.93 and a 12-month high of $83.12. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The company has a market cap of $3.41 billion, a PE ratio of 7.90 and a beta of 0.89. The stock has a 50-day moving average price of $47.31 and a 200-day moving average price of $47.61.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.